Search
for
Sort by
Research 30 of 1000+
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Toll-like receptor-targeted anti-tumor therapies: Advances and challenges
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Cutaneous Adverse Events of Targeted Anticancer Therapy: A Review of Common Clinical Manifestations and Management
- Hair Disorders Associated with Anticancer Agents
- Molecular targeted therapies for cancer: Sorafenib mono�therapy and its combination with other therapies (Review)
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- 129 Targeted inhibition of EGFR reduces anti-microbial defense mechanisms at the hair canal
- Skin toxicity of anti‐cancer therapy
- Drug-induced hair pigmentation: Clinical perspectives and updates
- Skin Manifestations of Targeted Antineoplastic Therapy
- Topical delivery of nanoemulsions for skin cancer treatment
- ANTI-CANCER MEDICINS (CLASSIFICATION AND MECHANISMS OF ACTION)
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy
- Tumor Angiogenesis and Anti-angiogenic Therapy
- Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model
- Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways
- Recent Developments in Luteolin-Loaded Nanoformulations for Enhanced Anti-Carcinogenic Activities: Insights from In Vitro and In Vivo Studies
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Advances and Perspectives on Bioelectronic and Atomic Nanogenerators for Anticancer Therapy
- Drug-Loaded Extracellular Vesicle-Based Drug Delivery: Advances, Loading Strategies, Therapeutic Applications, and Clinical Challenges
- The emerging roles of N6-methyladenosine (m6A) deregulation in polycystic ovary syndrome
- Noyes-Whitney Dissolution Model-Based pH-Sensitive Slow Release of Paclitaxel (Taxol) from Human Hair-Derived Keratin Microparticle Carriers